| Hulbert
Ranking |
 |
|
Peter Brimelow: 'A detailed review of Medical Technology Stock Letter (like the one we did a couple of years ago) reveals real strengths, as borne out by the fact that it's repeatedly been able to pull itself back into Hulbert's top-performing group in the past, through the incredible feat of registering year-on-year triple-digit gains .'
For full article, click here .
By Peter Brimelow,
|
|
|
|
Investment Scan |
|
 |
DNA Leads the Way | |
|
|
|
Full article is available only to MTSL subscribers. |
|
|
|
|
Biotech Sector Analysis |
|
|
 |
|
|
|
Published 7/24/08: DNA in Play?/Big Bios Deliver the Goods
Between the Roche buy-out offer for Genentech and a strong earnings season for Big Bios—during which they have really delivered the goods one after the other—the biotechs have been roaring in a tough market. We are not surprised, but nonetheless also pleased to see the strength spread throughout most of the biotechs, including several of the mid- and smaller-cap names. We have been saying for some time now that Big Bios, their strong revenue potential, and the long patent life on most of their drugs should position them to become market favorites
|
|
|
|
|
|
|
|
|
|
|
|
MTSL
In The News |
|
|
| Portfolio
Performance |
|
| | |
